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Abstract 
Unknown melanoma occurs as metastasis to skin, nodes or viscera, without a detectable cutaneous primary 
tumour. We reviewed our database of 4881 melanoma patients, diagnosed and followed up prospectively 
for a 33-year period. We identified 93 cases of metastatic melanoma without evidence of primary; 
however, five of these patients had a history of a previous excision of a presumed benign lesion without 
histological examination and were excluded from analyses. At diagnosis, metastases were cutaneous in 
35.3% of cases, nodal in 43.2% and visceral in 17% of cases; in 4.5% of patients, both skin and nodes were 
involved. In all cases, clinical inspection and staging procedures performed at diagnosis of metastatic 
disease failed to identify a primary melanoma. In 11 cases (11.8%), extensively regressed pigmented lesions 
(without evidence of melanoma cells at the histological examination) were documented; moreover, we 
identified in our series five patients with unknown primary affected by vitiligo. The 5-year and 10-year 
overall survival rates were 49.6 and 41.4%, respectively, with a median of 4.9 years. The 5-year and 10-year 
time to progression rates were 39.4 and 32.3%, respectively, with a median of 2.3 years. Survival was 
longer in females and showed significant differences among patients with skin, lymph node or visceral 
involvement at diagnosis. In melanoma patients, unknown primary represents a not so rare event, with an 
uncertain origin. We confirmed the relatively good prognosis of unknown primary melanoma patients, a 
fact that has to be taken into consideration for their management. 
   
Introduction 
Melanoma with unknown primary site (MUP), described for the first time in 1952 [1], is defined as 
histologically confirmed subcutaneous, lymph nodal or visceral metastatic melanoma with no evidence of 
concomitant cutaneous, mucosal or ocular primary lesion or previous skin tumour excised without 
histological examination [2]. 
Several theories have been proposed to clarify the pathogenesis of unknown primary melanoma. Some 
authors suggested that ectopic melanocytes located in lymph nodes can undergo malignant transformation 
[3,4]. Others recognize, instead, a role of an undetected primary melanoma that may have undergone 
spontaneous regression mediated by endogenous immune response [3]. 
In the literature, the incidence of MUP is rather frequent, ranging from 2 to 8% of all melanoma cases [3–
6]. However, the biological behaviour of the disease in these patients needs to be characterized. In several 
studies [7–9], prognosis seems not to be adversely affected by the lack of identification of primary 
melanoma; notably, unknown primary patients who presented with lymph nodal involvement show better 
prognosis than those with known primary melanoma [4,10,11]. 
In this study, we report our experience of 88 patients with diagnosis of MUP, with the aim to better clarify 
their clinical characteristics and outcome. 
   
Materials and methods 
Patient population and follow-up 
The clinical records of 4881 melanoma patients who were diagnosed and prospectively followed up at our 
Institution during a 33-year period (from January 1975 to December 2008) have been reviewed. We 
identified 93 patients with diagnosis of metastatic melanoma to lymph node, soft tissues or internal organs, 
without evidence of a primary lesion. 
Patient's age, sex, familiar or personal history of melanoma, history of vitiligo, spontaneous regression of 
nevi or previous excised skin lesions were recorded. Site of presentation, number of tumour-involved sites 
and clinical outcome were also evaluated. All the patients underwent clinical and radiological staging and 
follow-up procedures at our institution. At the time of diagnosis, patients underwent cutaneous, 
otorhinolaryngologist, ophthalmological and anogenital examination and brain and body imaging studies; 
after 1999, all patients underwent reverse transcription (RT)-PCR tyrosinase detection on peripheral blood. 
Afterwards, clinical and radiological follow-up was performed according to the guidelines in use [12,13]. 
Patients were staged on the basis of the AJCC classification [14]. MUP with a localized nodal or cutaneous–
subcutaneous involvement were considered stage III, whereas patients with cutaneous–subcutaneous 
disseminated metastases involvement of two or more nodal stations or with visceral metastases were 
classified as stage IV. 
  The control group consisted of stage III and stage IV patients with a documented primary 
cutaneous melanoma, diagnosed and treated during the same time interval. 
Tyrosinase detection 
Fifteen millilitres of blood were collected in EDTA (K3) tubes. The first few millilitres of each blood sample 
were discarded to avoid any possible contamination by normal skin melanocytes. Blood samples were 
processed within 2 h of collection. The RNA extraction, yield and nested RT-PCR procedures have been 
described elsewhere and all standard steps were taken to prevent carry-over contamination. A negative 
control (RNA from healthy donors blood) and a positive control (RNA from a melanoma cell line) were 
included with each batch of samples to verify a contamination-free environment and a faultless RT-PCR 
operating system. The integrity of the RNA for each sample was verified by RT-PCR with primers for human 
glyceraldehyde 3-phosphate dehydrogenase, as described elsewhere [15]. 
Statistical analysis 
The main endpoints calculated were: (i) time to progression (TTP), which is defined as the time between 
the diagnosis and the development of a new metastatic involvement; (ii) overall survival (OS), calculated 
from the date of histological diagnosis of metastatic MUP until death due to any cause. 
The Kaplan–Meier product-limit method was used to estimate curves for OS; the log-rank test was used to 
test differences between the survival curves. 
Univariate/multivariate analysis using the Cox proportional hazard regression model was performed to 
evaluate the impact of the known risk factors on the development and the distribution pattern of 
cutaneous metastases. The parameters included in the univariate/multivariate analysis model were clinical 
(age, sex, site of involvement); moreover, type of treatment (surgery alone vs. others) and baseline 
tyrosinase expression were also evaluated. The age was a continuous variable, the others categorical. 
   
Results 
Clinical features 
We identified 93 out of 4881 patients with histologically confirmed metastatic melanoma to lymph node, 
soft tissues and/or internal organs, without history of a primary melanoma excision. 
In all patients, clinical inspection and staging procedures performed at the time of diagnosis of metastatic 
disease failed to show a primary melanoma. In 11 cases (11.8%), we identified at clinical examination an 
extensively regressed pigmented lesion; however, pathological analyses failed to detect histological 
evidences of melanoma cells. Interestingly, three other patients showed large areas of vitiligo, without 
suspicious pigmented lesions, whereas two developed vitiligo during the follow-up; the global percentage 
of patients affected by vitiligo in these series was 5.4%. 
Five of the 93 patients were excluded from the study because they were referred to our department from 
other institutions with a history of a previous excision of a presumed benign lesion without histological 
examination. Two other patients experienced a removal of a body extremity (left foot amputation in one 
diabetic patient; traumatic excision of a finger due to an industrial accident in the other one); nevertheless, 
there was no history of suspected skin lesions in these body areas. 
Eighty-eight patients (1.8% of the entire series) were included in the study (55 male and 33 female). The 
median age was 60 years (range 17–88); median age was lower in women (56 years, range 23–85) than in 
men (63 years, range 17–88) (Table 1). 
 The sites of involvement at diagnosis can be summarized as follows: 31 patients (35.3%) showed 
cutaneous or subcutaneous metastases, which were localized in 27 patients and disseminated in the 
remaining four. Thirty-eight patients (43.2%) had only lymph node involvement, whereas in another four 
(4.5%) we found both lymph node and skin localizations. In the remaining 15 patients (17%), melanoma 
presented with visceral metastases, which were either disseminated (nine patients) or localized (brain, four 
cases; stomach, one case; lung, one case) (Table 1). According to the AJCC classification, one patient was 
stage IIIA, 53 were IIIB, 13 were IIIC and 21 were classified as stage IV (one with disseminated cutaneous 
metastases; three with disseminated subcutaneous localizations; two with two or more lymph nodal 
stations involved; 15 with visceral spreading). 
 Tyrosinase expression was evaluated at baseline condition in the 51 patients diagnosed from January 1999. 
Tyrosinase was positive in 12 patients, whereas the others showed negative results. 
None of our patients had a positive family history of melanoma. Five patients developed a new primary 
melanoma during the follow-up. Four were in-situ melanomas, without signs of regression or vascular 
invasion, and developed after a median time of 0.6 years (range 0.2 months–3.1 years) from the diagnosis 
of unknown primary. The last one was a nodular melanoma that developed in nasal mucosa after 7.8 years 
from the first diagnosis. In six patients, we documented a personal history of other nonmelanoma tumours 
(two breast carcinoma, one uterus, one lung, one kidney, one prostate adenocarcinoma). 
Treatment 
Surgery was the treatment of choice for 31 patients with cutaneous or subcutaneous localization, 36 
patients with lymph node involvement, three patients with both skin and lymph node metastases and six 
patients with visceral single metastases, who achieved a disease-free state; 36 of these patients received 
adjuvant immunotherapy (14) or chemoimmunotherapy (22). The remaining 12 metastatic patients were 
treated with chemotherapy or chemoimmunotherapy according to the current protocols of treatment. 
Outcome 
The overall 5-year and 10-year survival rates of MUP patients were 49.6 and 41.4%, respectively, with a 
median survival rate of 4.9 years (Fig. 1a). Female patients had a better survival rate (median 6.5 years; 5 
years 52.4%; 10 years 48.1%) than male patients (median 3.2 years; 5 years 47.8%; 10 years 35.4%) (Fig. 
1b); however, these differences were not statistically significant. Survival was significantly different among 
patients with skin (median 8.6 years), lymph node (median 17.4 years) or visceral (median 1.0 years) 
involvement at the time of diagnosis. MUP with visceral metastases at diagnosis showed an OS significantly 
lower than the other MUP patient groups (P<0.001) (Fig. 1c). 
The 5-year and 10-year TTP rates were 39.4 and 32.3%, respectively, with a median TTP of 2.3 years (Fig. 
1d). TTP was higher, although not statistically significant, in females (median 4.2 years; 5 years and 10 years 
43.7%) than in males (median 2.2 years; 5 years 37.2%; 10 years 24.8%) (Fig. 1e). Site of involvement at the 
time of diagnosis did not affect the percentage of patients who developed new metastasis during follow-
up; however, patients with early skin and/or lymph node involvement developed new recurrence later than 
those with visceral metastases (4.2 years, 2.3 years and 1.4 years, respectively) (Fig. 1f). 
When stage III MUP patients were compared with control group, we observed a significantly higher OS (5-
year survival 60.2 vs. 42.2%; 10-year survival 51.7 vs. 33.8%; P=0.0171) (Fig. 2a). OS was also increased in 
stage IV MUP patients (1-year survival 52.2 vs. 40.4%; 5-year survival 16.2 vs. 9.7%), even if these 
differences were not statistically significant (Fig. 2b). 
  
 
 The disease course was influenced by tyrosinase status at baseline; univariate analysis showed a TTP 
significantly lower (P=0.016) in patients with positive tyrosinase at diagnosis than in those with negative 
results. 
Multivariate analysis 
Multivariate analysis on entire cohort of patients showed a significant OS difference between patients with 
soft tissue and visceral metastases (P=0.05), whereas no differences were found in TTP (Table 2). 
In 51 of 88 patients, baseline tyrosinase was included as a parameter in multivariate analysis. Despite the 
lower number of patients, analysis confirmed that the site of involvement at the time of diagnosis (soft 
tissues vs. visceral metastases) was the most powerful prognostic indicator associated with significant OS 
differences (P=0.0021) (Table 2). Similarly, as shown earlier on the entire cohort of patients, soft tissue 
versus visceral involvement did not affect TTP. 
Multivariate analyses showed that baseline tyrosinase detection plays a significant prognostic role on TTP, 
with a risk ratio of 2.56 (P=0.046) (Table 2), whereas was not significant in terms of OS. 
 
Discussion 
The finding of patients with diagnosis of metastatic melanoma without evidence or previous history of 
suspicious pigmented skin lesions is a relatively frequent event, which assesses for 1.8% of all melanoma 
cases in our series. This percentage is in agreement with that reported by other studies [3–6], although the 
incidence of unknown primary is estimated to be approximately 8–9% by authors that take into account 
only patients with lymph node involvement [7,16]. In our experience, in agreement with the majority of 
published series [3,4,17,18], patients with unknown primary were predominantly middle-aged males. In 
almost half of the cases, the first site of presentation was a lymph nodal mass, but also cutaneous or 
subcutaneous localizations were frequent; on the contrary, visceral metastases were found at diagnosis in 
only 18% of patients. 
We classified our MUP patients according to the rules of the AJCC classification, as recently reported 
[5,6,16]. However, the use of AJCC in the classification of MUP could be misleading. Actually, the current 
AJCC system classifies patients with locoregional skin metastases as stage IIIb and patients with distant skin 
localizations as stage IV [14]. The site of primary melanoma plays an important role in the definition of 
cutaneous or lymph nodal involvement as locoregional (stage III) or distant (stage IV) and, consequently, 
the absence of a known site of primary melanoma could lead to incorrect classification. We arbitrarily 
classified as stage III all MUP patients with a single lymph-nodal or soft-tissue metastasis; whereas, patients 
with involvement of two or more nodal stations, disseminated cutaneous or subcutaneous metastases or 
with visceral localizations were classified as stage IV. As we did not find any sign of primary melanoma in 
more than 77% of our patients, some stage IV patients could be erroneously assigned to stage III, with 
considerable implications in their treatment and follow-up. However, despite this likely incorrect 
classification, we confirmed the better prognosis of MUP patients, when compared with those with known 
primary site [4,6,9,16]. Our data show higher OS and TTP in patients with unknown primary, with a further 
survival advantage in females. We suppose that these differences could be more underestimated in the 
light of the above-mentioned classification mistakes. 
Although our data are not statistically significant on account of the small number of patients, no differences 
in the percentage of patients with progressive disease were observed depending on the site of involvement 
at the time of diagnosis (skin, lymph node or viscera); however, the TTP to new metastatic sites was 
significantly higher in patients with skin involvement at diagnosis (4.2 years) than in those with lymph nodal 
or visceral metastases (2.3 and 1.4 years, respectively). This observation could have an impact on 
therapeutic strategies and can support, in our opinion, the role of local therapies in the management of 
MUP patients with disease restricted to the skin. In contrast, the predictive role of the first site of 
involvement (soft tissues vs. viscera) in OS was also confirmed in multivariate analysis. Moreover, we 
confirmed a positive predictive value for surgery, whereas no outcome differences were found between 
patients that underwent adjuvant therapy and those treated with surgery alone. The role of adjuvant 
therapy in MUP patients remain unclear; in fact, the small size of the majority of published series precluded 
a comparative analysis of survival between the different group of patients [4,5]. 
Recently, the value of serum S100 protein as sensitive and specific marker to detect melanoma metastases 
has been confirmed [19,20], and its inclusion in the baseline staging of MUP patients has been 
recommended [21]. Staging procedures in use at our department do not include S-100 determination, but, 
since 1999, tyrosinase detection is made on peripheral blood. At the time of diagnosis, positive results were 
found in 12 of 51 MUP patients. Univariate analysis confirmed that tyrosinase status at baseline influenced 
the disease outcome: patients with positive results at diagnosis showed a TTP significantly lower than 
patients with negative results (P=0.016). Multivariate analyses confirmed the prognostic role of baseline 
tyrosinase in TTP, with a risk ratio of 2.56 (P=0.046). These data are in agreement with our previous 
observations. The relationship between tyrosinase results and disease status has been shown by our group, 
as well as the predictive role of this marker and its usefulness in the monitoring of stage III patients [15,22]. 
Multivariate analyses including the tyrosinase variable was not performed on the totality of cases; 
however, this cohort seems to be representative of the entire MUP population included in this study. The 
remaining parameters analyzed did indeed show superimposable results. 
To date, the aetiology of MUP remains unexplained; in literature, two main hypotheses have been 
proposed: (i) complete spontaneous regression of the primary melanoma [23] and (ii) primary origin from 
melanocytes in lymph nodes or viscera [24]. 
The first hypothesis is supported by the demonstration of partially regressed pigmented lesion in several 
MUP patients [4]. We found lesions suggestive for a melanoma with regression in 11 of our patients 
(11.8%). Moreover, others five patients (5.4%) showed large areas of vitiligo, even if we did not find any 
suspicious pigmented lesion; this percentage is higher in comparison with both the general population 
(0.5–1%) [25,26] and the patients affected by melanoma with known primary site (2.8% in patients 
followed up at our institution during the last 33-year period). Therefore, it is possible that areas of vitiligo 
could hide a primary melanoma in some patients. Noteworthy, in melanoma patients it has been shown 
that vitiligo has a positive prognostic role [26,27]. 
The hypothesis of MUP origin from melanocytes in lymph node or viscera [23] has to be confirmed. It could 
be supported by the fact that in the majority of patients with unknown primary, clinical and radiological 
examination performed to detect primary lesion resulted normal. In a large study published by Lenzi et al. 
[28], including patients affected by different metastatic solid tumours, the primary site was identified only 
in less than a quarter of investigated patients. Furthermore, in our experience, radiological procedures, 
otorhinolaryngologist, ophthalmological and anogenital, as well as cutaneous examinations failed in the 
identification of suspect lesions in the vast majority of cases. Therefore, the real cost-effectiveness of these 
tests and their importance in the management of MUP patients is questionable. 
Our experience confirms that unknown primary is not such a rare event; the aetiology remains uncertain 
and, probably, we have to take in account different mechanisms. Probably, immune system response plays 
a crucial role. However, we confirmed the relatively good prognosis of MUP, which has key implications 
both for counselling and management of these patients. Finally, in consideration of the large percentage of 
failure in the search of primary tumour, we advise a careful examination of skin and mucosae but 
discourage thorough expensive and time-consuming examinations other than those used in the current 
staging procedures of patients with melanoma of known primary site. 
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